BME — BLACKROCK HEALTH SCIENCES TR

Public company

Sign in to save1 tracked investor reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying BME?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
95
Institutional Conviction
Net accumulation · 1 buying vs 0 selling last quarter
60
Macro Tailwind
Macro conditions are mixed for this sector
57
Why? — Evidence & Confidence ▾

Of 1 tracked investors who changed their BME position last quarter, 1 bought and 0 sold (100% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 57/100 in a Contraction regime).

Supporting evidence
  • +1 tracked investor added or increased positions last quarter (Ken Griffin)
  • +1 tracked investors reported holding BME at their latest filing
  • +Macro Health is 57/100 in a Contraction regime — historically acceptable for this sectorsource
Contradicting evidence — always shown
  • 13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/6/2026.

About BLACKROCK HEALTH SCIENCES TR (BME)

BLACKROCK HEALTH SCIENCES TR (BME) appears in the most recent 13F filings of 1 tracked institutional investor. The largest disclosed position is held by Izzy Englander (Millennium Management), valued at $528,150. Across recent filings, tracked investors recorded 3 new positions, 0 increased, 2 reduced, and 2 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in BME

43
/100
Mixed Activity
Added / Increased3
Reduced2
Exited2
BearishBullish
Crowded Trade Score™

How many top investors track BME

7
/100
Undiscovered
1investor

Only 1 tracked investor report this position.

UndiscoveredCrowded
151015+

BME Ownership Composition

How BLACKROCK HEALTH SCIENCES TR is held across tracked investor types, based on reported 13F positions.

Dominant Type
Multi-Strategy / Quant
100% of tracked value
Institutions
1
tracked investors
Total Reported
$354.9K
combined 13F value
Types1
  • Multi-Strategy / Quant100.0%
Multi-Strategy / Quant(1)
100.0%

Tracked investors currently reporting BME

1 tracked investor has since exited this position — listed separately below.

  • Ken GriffinJun 30, 2026
    Citadel Advisors
    Shares
    8.3K
    Value
    $354.9K
    % Portfolio
    0.00%

Previously held BME

These investors reported BME in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.

InvestorFirmLast reported sharesValue thenLast held
Izzy EnglanderMillennium Management10.4K$429.5KDec 31, 2025

Recent activity

Frequently asked questions

How many institutional investors hold BME?
1 tracked institutional investor disclosed a position in BME (BLACKROCK HEALTH SCIENCES TR) in their most recent 13F filing.
Who is the largest institutional holder of BME?
Izzy Englander, Millennium Management, holds the largest disclosed position in BME, valued at $528,150.
Did institutional ownership of BME increase or decrease?
Across recent 13F filings, tracked investors recorded 3 new positions, 0 increased, 2 reduced, and 2 fully exited BME.
Where does this BME ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.